pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,146 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1184Endpoints903BioPharma Dive348BioSpace317Fierce Biotech301onclive165raps106globenewswire health73
therapy area
allOncology7772Rare Disease1891Cardiology1780Immunology1512Hematology1329Vaccines1207Pulmonology
  • Eugene Braunwald, the "father of modern cardiology," remembered for pioneering heart-attack prevention and a lab scandal
    Eugene Braunwald, widely called the father of modern cardiology, died at 96 on April 22. His career reshaped how doctors treat heart disease and he is celebrated as the most influential cardiologis…
    STAT · 4mo agoNeutral↗ source
  • Experts caution limited knowledge of hantavirus after outbreak on African offshore cruise ship
    Health officials are monitoring a hantavirus outbreak on the MV Hondius, a cruise ship that was moored off the western coast of Africa. The situation has drawn attention because passengers were con…
    STAT · 4mo agoNeutral↗ source
← prev
page 80 of 86
next →
fda recalls70
fda medwatch60
fda press38
1203
Psychiatry & CNS870
Ophthalmology503
Pain483
Endocrinology & Metabolism481
Infectious Disease449
FDA approves nivolumab plus AVD for untreated advanced-stage Hodgkin lymphoma
Dr. Alex Herrera, a professor and chief of lymphoma at City of Hope, highlighted the recent FDA clearance of the combination of nivolumab with the chemotherapy regimen AVD for patients with newly d…
onclive · 4mo agoApprovalPositive↗ source
  • Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancer
    The DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…
    onclive · 4mo agoPositive readoutPositive↗ source
  • White House drug strategy endorses treatment but tightens funding for fentanyl test strips
    The White House released a new drug‑policy document on May 4 that lists public‑health measures such as wider access to the overdose‑reversal drug naloxone, medication‑assisted treatment, and the di…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Experts favor quadruplet regimens for newly diagnosed multiple myeloma, but transplant role remains debated
    At a recent multiple myeloma meeting, Dr. Ajai Chari of UCSF reviewed current frontline treatment strategies for newly diagnosed patients. He said that data from several phase-3 trials have shifte…
    onclive · 4mo agoNeutral↗ source
  • FDA accepts supplemental NDA for taletrectinib targeting ROS1‑positive lung cancer
    The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for taletrectinib, a targeted therapy aimed at patients with ROS1‑positive non‑small cell lung cancer. The fi…
    onclive · 4mo agoRegulatoryNeutral↗ source
  • Administration releases detailed report on most-favored-nation drug pricing, projects $529 billion savings
    The White House Council of Economic Advisers released its most detailed analysis yet of the administration's most-favored-nation drug pricing policy. The report defines the MFN pricing approach, w…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Phase 3 MANEUVER trial shows pimicotinib improves response and pain in advanced TGCT, supporting FDA NDA acceptance
    The phase 3 MANEUVER study evaluated pimicotinib in patients with advanced diffuse tenosynovial giant cell tumor. The trial compared the oral agent to placebo and collected both clinical and patien…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Higher PD-L1 levels linked to poorer outcomes in EGFR-mutated NSCLC treated with first-line osimertinib
    Dr. Jonathan Wennan Lee, a chief hematology/oncology fellow at Weill Cornell Medicine, discussed the emerging role of PD-L1 as a predictive biomarker for first-line osimertinib resistance in EGFR-m…
    onclive · 4mo agoNegative readoutNeutral↗ source
  • Experts discuss next-generation pathology and precision care for non-small cell lung cancer in new CME podcast
    The CME podcast released on May 6, 2026 brings together Sanja Dacic, Isabel Preeshagul, and Soo-Ryum (Stewart) Yang to review recent advances in pathology for non-small cell lung cancer. The exper…
    onclive · 4mo agoNeutral↗ source
  • PeaceHealth abandons plan to outsource Oregon emergency doctors to ApolloMD after lawsuit and local opposition
    PeaceHealth, a nonprofit health system in Oregon, announced Wednesday that it will not move its emergency department staffing to the national physician staffing firm ApolloMD. The decision reverse…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
    Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
    onclive · 4mo agoNeutral↗ source
  • STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
    Sanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.
    STAT · 4mo ago↗ source
  • Dr Sznol on Biomarkers of Response in Metastatic Melanoma
    Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.
    onclive · 4mo ago↗ source
  • Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery
    The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.
    onclive · 4mo ago↗ source
  • STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
    Color Health, which coordinates cancer screening, is moving into a gap it observed — obtaining and coordinating actual cancer care.
    STAT · 4mo ago↗ source
  • Why the FDA is authorizing fruit-flavored vapes
    Marty Makary says he was "skeptical initially" about flavored vapes but that age-gating technology could limit their use.
    STAT · 4mo ago↗ source
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 4mo ago↗ source
  • STAT+: When the path to good AI is littered with bad data
    In this edition of AI Prognosis, Brittany Trang raises the question: What kind of health data would we need to train AI models to be useful in health care.
    STAT · 4mo ago↗ source
  • ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
    Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
    onclive · 4mo ago↗ source
  • STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
    Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
    STAT · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
    One of the most powerful pharmaceutical lobbying groups is launching a new seven-figure advertising blitz targeting a federal drug discount program
    STAT · 4mo ago↗ source
  • Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management
    Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.
    onclive · 4mo ago↗ source
  • Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration
    New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.
    onclive · 4mo ago↗ source